Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Yamada
K
K
Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Kanba
S
S
Ohnishi
K
K
Ashikari
I
I
Yagi
G
G
Asai
M
M
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D015259:Dopamine Agents; D000547:Amantadine; D006719:Homovanillic Acid